News & Videos - SPARK THERAPEUTICS INC.

NeuExcell Therapeutics and Spark Therapeutics Announce Research Collaboration Agreement to Develop a Novel Gene Therapy for Huntington's Disease

-- Using NeuExcell's neuroregenerative gene therapy platform, the collaboration aims to develop an effective and safe treatment for patients suffering from Huntington's Disease.

-- Spark Therapeutics' excellence in R&D and proprietary adeno-associated virus (AAV) vector gene therapy platform may advance the development of the program and...

Lifshitz & Miller LLP Announces Investigation of AVEO Pharmaceuticals, Inc., CenturyLink, Inc., Inogen, Inc., Mattel, Inc., Spark Therapeutics, Inc., Stamps.com, Inc., Syneos Health, Inc., and Weight Watchers, Inc. PR Newswire NEW YORK, March 22, 2019 NEW YORK , March 22, 2019 /PRNewswire/ -- AVEO Pharmaceuticals, Inc. (AVEO) Lifshitz & Miller announces investigation into possible securities laws violations in connection with the FDA seeking additional survival data concerning tivozanib echoing...

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Spark Therapeutics, Inc. - ONCE PR Newswire NEW YORK, March 11, 2019 NEW YORK , March 11, 2019 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City , is investigating Spark Therapeutics, Inc. ("Spark Therapeutics" or the "Company") (NasdaqGS: ONCE) relating to the sale of the Company to Roche...

NEW YORK, June 21, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Second Sight Medical Products, Inc. (NASDAQ:EYES), ICF International, Inc. (NASDAQ:ICFI), Morningstar, Inc. (NASDAQ:MORN), Spark Therapeutics, Inc. (NASDAQ:ONCE), Natera, Inc. (NASDAQ:NTRA), and Kadmon Holdings, Inc. (NYSE:KDMN), including updated fundamental summaries,...

NEW YORK, NY / ACCESSWIRE / February 20, 2018 / Spark Therapeutics, Inc. (NASDAQ: ONCE ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 20, 2018, at 8:30 AM Eastern Time. To listen to the event live or access a replay of the call - visit https://www.investornetwork.com/company/22395 . To receive updates for this company you can register by emailing [email protected] or by clicking get investment info from the company's profile. About Investor...

Spark Therapeutics CEO Jeff Marrazzo speaks to CNBC's Meg Tirrell about the biotech company's hemophilia treatments and the potential for gene therapies. » Subscribe to CNBC: http://cnb.cx/Subscri......

NEW YORK, NY / ACCESSWIRE / November 7, 2017 / Spark Therapeutics, Inc. (NASDAQ: ONCE ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 7, 2017 at 8:30 AM Eastern Time. To listen to the event live or access a replay of the call - visit https://www.investornetwork.com/company/22395 . To receive updates for this company you can register by emailing [email protected] or by clicking get investment info from the company's profile. About Investor...

VIDEO FINANCIAL REPORTING Why invest in is the first financial video platform where you can easily search through thousands of videos describing global ......

PHILADELPHIA, Jan. 26, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced today that members of company management will present at the following February conferences: European Association for Haemophilia and Allied Disorders (EAHAD), at the Marriott Rive Gauche Hotel & Conference Centre in Paris Katherine A. High, M.D., president and chief scientific officer, will participate...

FDA grants request to amend orphan drug designation for voretigene neparvovec to encompass all Inherited Retinal Disease (IRD) caused by biallelic RPE65 mutations, which is aligned with proposed indication New longer-term, four-year Phase 1 clinical data show durability of effect of one-time administration of investigational voretigene neparvovec Natural history study confirms degenerative course of IRD caused by biallelic RPE65 mutations and enhances understanding of the clinical significance...

PHILADELPHIA, Jan. 04, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced that it has earned a $15 million payment from Pfizer Inc. (NYSE:PFE) for achieving a pre-specified safety and efficacy profile development milestone in the ongoing hemophilia B Phase 1/2 trial of investigational SPK-9001 . SPK-9001 has received breakthrough therapy and orphan product designations...

PHILADELPHIA, Jan. 03, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced today that Jeffrey D. Marrazzo, chief executive officer, is presenting at the 35 th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 10, at 11:30 a.m. PST, at the Westin St. Francis Hotel, in San Francisco, California. A webcast of Marrazzo’s presentation will be available live on...

WATERTOWN, Mass., Dec. 05, 2016 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company developing a novel class of targeted antigen-specific immune therapies, announced today that it will hold a conference call at 9:00 a.m. Eastern Time this morning to discuss a license agreement that provides Spark Therapeutics with exclusive worldwide rights to Selecta’s proprietary Synthetic Vaccine Particles (SVP™) platform technology for co-administration...

PHILADELPHIA, Dec. 05, 2016 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced the appointment of John Furey to the newly created position of chief operating officer. Mr. Furey will be responsible for global commercial operations, medical affairs, technology development and technical operations. He will report to Jeffrey D. Marrazzo, chief executive officer, and will be an...

Exclusive use of Selecta’s Synthetic Vaccine Particles (SVP™) platform technology provided to Spark Therapeutics for co-administration with up to five gene therapy targets, including FVIII for hemophilia A SVP may enhance gene therapies by enabling repeat dosing and mitigating other potential immune responses to an AAV capsid PHILADELPHIA and WATERTOWN, Mass., Dec. 05, 2016 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE) and Selecta Biosciences, Inc. (NASDAQ:SELB) today announced a...

Together, all nine participants have reduced infusions of factor IX concentrates by 99 percent over cumulative 1,650 days Seven infused participants who have progressed to at least 12 weeks post-vector administration as of Nov. 30, 2016 have a mean steady-state factor IX activity level greater than 28 percent PHILADELPHIA, Dec. 03, 2016 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE) and Pfizer Inc. (NYSE:PFE) announced updated preliminary data today from the first nine infused participants...

PHILADELPHIA, Nov. 30, 2016 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced today that Katherine High, M.D., president and chief scientific officer of Spark Therapeutics, and Lindsey A. George, M.D., hematologist and attending physician at the Children’s Hospital of Philadelphia, will present updated Phase 1/2 clinical trial data for SPK-9001 in hemophilia B at the 58th...

First seven participants, through a combined 103 weeks of observation as of Aug. 4, 2016, did not need infusions of factor IX concentrates to prevent bleeding Updated SPK-9001 data in hemophilia B to be presented at the Plenary Scientific Session at 58th American Society of Hematology Annual Meeting PHILADELPHIA and NEW YORK, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE) and Pfizer Inc. (NYSE:PFE) announced today that Lindsey A. George, M.D., a hematologist and attending...

Completion of Biologics Licensing Application (BLA) submission for investigational candidate voretigene neparvovec on track for early 2017 Company makes progress across multiple programs, including its hemophilia franchise PHILADELPHIA, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company seeking to transform the lives of patients with debilitating genetic diseases by developing investigational, potentially one-time, life-altering...

PHILADELPHIA, Oct. 31, 2016 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company seeking to transform the lives of patients with debilitating genetic diseases by developing investigational, potentially one-time, life-altering treatments, announced today that members of company management or key investigators will present at the following upcoming conferences: Genome Editing for Gene and Cell Therapy, a Herrenhausen Symposium, at the Herrenhausen Palace...